PMID- 37517135
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20231010
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 203
DP  - 2023 Sep 15
TI  - Transcatheter Aortic Valve Implantation in Mixed Aortic Valve Disease: A 
      Multicenter Study.
PG  - 394-402
LID - S0002-9149(23)00601-X [pii]
LID - 10.1016/j.amjcard.2023.07.064 [doi]
AB  - Mixed aortic valve disease (MAVD), defined by the concurrent presence of aortic 
      stenosis (AS) and insufficiency is frequently seen in patients who have undergone 
      transcatheter aortic valve implantation (TAVI). However, studies comparing the 
      outcomes of TAVI in MAVD versus isolated AS have demonstrated conflicting 
      results. Therefore, we aim to assess the outcomes of TAVI in patients with MAVD 
      in comparison with those with isolated severe AS. Patients who underwent native 
      valve TAVI for severe AS at 3 tertiary care academic centers between January 2012 
      and December 2020 were included and categorized into 3 groups based on 
      concomitant aortic insufficiency (AI) as follows: group 1, no AI; group 2, mild 
      AI; and group 3, moderate to severe AI. Outcomes of interest included all-cause 
      mortality and all-cause readmission rates at 30 days and 1 year. Other outcomes 
      include bleeding, stroke, vascular complications, and the incidence of 
      paravalvular leak at 30 days after the procedure. Of the 1,588 patients who 
      underwent TAVI during the study period, 775 patients (49%) had isolated AS, 606 
      (38%) had mild AI, and 207 (13%) had moderate to severe AI. Society of Thoracic 
      Surgeons risk scores were significantly different among the 3 groups (5% in group 
      1, 5.5% in group 2, and 6% in group 3, p = 0.003). Balloon-expandable valves were 
      used in about 2/3 of the population. No statistically significant differences in 
      30-day or 1-year all-cause mortality and all-cause readmission rates were noted 
      among the 3 groups. Post-TAVI paravalvular leak at follow-up was significantly 
      lower in group 1 (2.3%) and group 2 (2%) compared with group 3 (5.6%) (p = 0.01). 
      In summary, TAVI in MAVD is associated with comparable outcomes at 1 year 
      compared with patients with isolated severe AS.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Guddeti, Raviteja R
AU  - Guddeti RR
AD  - Division of Cardiovascular Diseases, Creighton University School of Medicine, 
      Omaha, Nebraska.
FAU - Gill, Gauravpal S
AU  - Gill GS
AD  - Division of Cardiovascular Diseases, Creighton University School of Medicine, 
      Omaha, Nebraska.
FAU - Parekh, Jai D
AU  - Parekh JD
AD  - Division of Cardiovascular Diseases, University of Iowa, Iowa City, Iowa.
FAU - Jhand, Aravdeep S
AU  - Jhand AS
AD  - Division of Cardiovascular Diseases, University of Nebraska Medical Center, 
      Omaha, Nebraska.
FAU - Walters, Ryan W
AU  - Walters RW
AD  - Department of Clinical Research, Creighton University School of Medicine, Omaha, 
      Nebraska.
FAU - Panaich, Sidakpal S
AU  - Panaich SS
AD  - Division of Cardiovascular Diseases, University of Iowa, Iowa City, Iowa.
FAU - Goldsweig, Andrew M
AU  - Goldsweig AM
AD  - Division of Cardiovascular Diseases, University of Nebraska Medical Center, 
      Omaha, Nebraska.
FAU - Alla, Venkata Mahesh
AU  - Alla VM
AD  - Division of Cardiovascular Diseases, Creighton University School of Medicine, 
      Omaha, Nebraska. Electronic address: venkataalla@creighton.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230729
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
CIN - Am J Cardiol. 2023 Nov 1;206:357-359. PMID: 37735057
MH  - Humans
MH  - *Transcatheter Aortic Valve Replacement/methods
MH  - Aortic Valve/surgery
MH  - *Heart Valve Prosthesis/adverse effects
MH  - Treatment Outcome
MH  - *Aortic Valve Stenosis
MH  - *Aortic Valve Insufficiency/epidemiology/surgery/etiology
MH  - Postoperative Complications/etiology
OTO - NOTNLM
OT  - aortic stenosis
OT  - mixed aortic valve disease
OT  - transcatheter aortic valve implantation
COIS- Declaration of Competing Interest Dr. Goldsweig reports consulting with Inari and 
      speaker fees from Edwards and Philips. The remaining authors have no competing 
      interests to declare.
EDAT- 2023/07/31 00:41
MHDA- 2023/08/28 06:42
CRDT- 2023/07/30 18:02
PHST- 2023/03/04 00:00 [received]
PHST- 2023/07/06 00:00 [revised]
PHST- 2023/07/13 00:00 [accepted]
PHST- 2023/08/28 06:42 [medline]
PHST- 2023/07/31 00:41 [pubmed]
PHST- 2023/07/30 18:02 [entrez]
AID - S0002-9149(23)00601-X [pii]
AID - 10.1016/j.amjcard.2023.07.064 [doi]
PST - ppublish
SO  - Am J Cardiol. 2023 Sep 15;203:394-402. doi: 10.1016/j.amjcard.2023.07.064. Epub 
      2023 Jul 29.